89 related articles for article (PubMed ID: 24950134)
1. Intracellular delivery of recombinant arginine deiminase (rADI) by heparin-binding hemagglutinin adhesion peptide restores sensitivity in rADI-resistant cancer cells.
Wu FL; Yeh TH; Chen YL; Chiu YC; Cheng JC; Wei MF; Shen LJ
Mol Pharm; 2014 Aug; 11(8):2777-86. PubMed ID: 24950134
[TBL] [Abstract][Full Text] [Related]
2. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
3. RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells.
Wu FL; Liang YF; Chang YC; Yo HH; Wei MF; Shen LJ
J Biomed Sci; 2011 Apr; 18(1):25. PubMed ID: 21453546
[TBL] [Abstract][Full Text] [Related]
4. Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase.
Shen LJ; Lin WC; Beloussow K; Shen WC
Cancer Lett; 2003 Mar; 191(2):165-70. PubMed ID: 12618329
[TBL] [Abstract][Full Text] [Related]
5. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase.
Shen LJ; Beloussow K; Shen WC
Cancer Lett; 2006 Jan; 231(1):30-5. PubMed ID: 16356828
[TBL] [Abstract][Full Text] [Related]
6. Recombinant arginine deiminase reduces inducible nitric oxide synthase iNOS-mediated neurotoxicity in a coculture of neurons and microglia.
Yu HH; Wu FL; Lin SE; Shen LJ
J Neurosci Res; 2008 Oct; 86(13):2963-72. PubMed ID: 18627024
[TBL] [Abstract][Full Text] [Related]
7. Depletion of arginine by recombinant arginine deiminase induces nNOS-activated neurotoxicity in neuroblastoma cells.
Lin SE; Wu FL; Wei MF; Shen LJ
Biomed Res Int; 2014; 2014():589424. PubMed ID: 25126568
[TBL] [Abstract][Full Text] [Related]
8. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma.
Kim JH; Kim JH; Yu YS; Kim DH; Min BH; Kim KW
Oncol Rep; 2007 Dec; 18(6):1373-7. PubMed ID: 17982619
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19α protein.
Lee H; Park G; Kim S; Son B; Joo J; Park HH; Park TH
Appl Microbiol Biotechnol; 2022 Nov; 106(22):7531-7545. PubMed ID: 36227339
[TBL] [Abstract][Full Text] [Related]
11. Characterization of mycoplasma arginine deiminase expressed in E. coli and its inhibitory regulation of nitric oxide synthesis.
Noh EJ; Kang SW; Shin YJ; Kim DC; Park IS; Kim MY; Chun BG; Min BH
Mol Cells; 2002 Feb; 13(1):137-43. PubMed ID: 11911465
[TBL] [Abstract][Full Text] [Related]
12. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
13. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells.
Agrawal V; Woo JH; Mauldin JP; Jo C; Stone EM; Georgiou G; Frankel AE
Anticancer Drugs; 2012 Jan; 23(1):51-64. PubMed ID: 21955999
[TBL] [Abstract][Full Text] [Related]
15. Aspergillus nidulans thermostable arginine deiminase-Dextran conjugates with enhanced molecular stability, proteolytic resistance, pharmacokinetic properties and anticancer activity.
El-Sayed ASA; Shindia AA; Zeid AAA; Yassin AM; Sitohy MZ; Sitohy B
Enzyme Microb Technol; 2019 Dec; 131():109432. PubMed ID: 31615671
[TBL] [Abstract][Full Text] [Related]
16. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
[TBL] [Abstract][Full Text] [Related]
17. Study of the intracellular delivery mechanism of a pH-sensitive peptide modified with enhanced green fluorescent protein.
Chiu PC; Hsieh PY; Kang JW; Chang PH; Shen LJ
J Drug Target; 2020 Apr; 28(4):408-418. PubMed ID: 31524004
[TBL] [Abstract][Full Text] [Related]
18. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
[TBL] [Abstract][Full Text] [Related]
19. Recombinant arginine deiminase as a potential anti-angiogenic agent.
Beloussow K; Wang L; Wu J; Ann D; Shen WC
Cancer Lett; 2002 Sep; 183(2):155-62. PubMed ID: 12065090
[TBL] [Abstract][Full Text] [Related]
20. Rapid enzymatic assays for L-citrulline and L-arginine based on the platform of pyrophosphate detection.
Kameya M; Asano Y
Enzyme Microb Technol; 2014 Apr; 57():36-41. PubMed ID: 24629265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
